ClinicaliQ Trial Snapshot
- Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) — Recruiting • Phase III • Cardiology / Cardiovascular • NCT07428499.
- Treatment being tested: ADX-324 is a novel therapy being evaluated for long-term safety and efficacy in hereditary angioedema (HAE) Types I and II, building on data from the completed Phase 3 ADX-324-301 trial through this extension study.
- Patient eligibility: The study enrolls participants who have successfully completed the preceding Phase 3 ADX-301 trial, ensuring a well-characterised population with confirmed HAE Types I or II and documented tolerance of the investigational drug.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.
Eligibility Snapshot
- : * Have a documented diagnosis of HAE (Type I or II) * Completed Study ADX-324-301 * Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.